Alex Dale, Author at Labiotech.eu

About

A former journalist intern at Labiotech, Alex now works as a copywriter in healthcare advertising. When he’s not writing, he enjoys playing sports and long-distance cycling.

Articles by Alex Dale

News and Trends 7 Sep 2017

Spanish Biotech Receives €4.2 Million To Continue Development of Anti-Cancer Peptide

Investment will allow Peptomyc to continue the development of their peptide cancer therapy with reduced side effects. Peptomyc gained €4.2M from a group of investors led by Alta Life Sciences at Series A of fundraising. Peptomyc is part of the growing biotech hub in Barcelona, Spain. A spin-out was formed following research carried out at […]

September 7, 2017 - 2 minutesmins - By Alex Dale

News and Trends 7 Sep 2017

Verona Achieves Successful Results for Phase IIa Trial of Deadly Lung Disease Drug

A study of Verona’s combination therapy for COPD observed a clinical improvement in lung function and faster onset-of-action. Verona filed for its US IPO and dosed the first patient in the trial in April, and it is now receiving initial results. This could explain a recent increase in their share price on the London Stock Exchange by […]

September 7, 2017 - 2 minutesmins - By Alex Dale

News and Trends 6 Sep 2017

Tiziana‘s Antibody Formulation Enters Phase IIa Trial for Liver Disease Treatment

Tiziana makes moves towards a €37B market with an oral monoclonal antibody (mAb) formulation to treat non-alcoholic steatohepatitis (NASH) . Tiziana, which has previously developed compounds targeting the second most deadly form of cancer, has produced a novel formulation of the anti-CD3 mAb, Foralumab. The biologic will be tested in patients with NASH and other […]

September 6, 2017 - 3 minutesmins - By Alex Dale

Resources

Categories

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Alex Dale

About

Articles by Alex Dale

Spanish Biotech Receives €4.2 Million To Continue Development of Anti-Cancer Peptide

Verona Achieves Successful Results for Phase IIa Trial of Deadly Lung Disease Drug

Tiziana‘s Antibody Formulation Enters Phase IIa Trial for Liver Disease Treatment

Subscribe to our newsletter to get the latest biotech news!

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Alex Dale

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!